Clinical trials
Chronic Hepatitis B clinical trials
Below are recruiting chronic hepatitis b clinical trials, each written for real people, not researchers. We’re tracking 171 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06457477Recruiting
PD-1 antibody and peginterferon for chronic hepatitis B
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Beijing, Beijing MunicipalityAges 18–65 - NCT06550622Recruiting
Better Detection of Hepatitis B Virus After Treatment
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT07059403RecruitingPhase 1
Safety and dose study of a new hepatitis B vaccine in healthy adults
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Herston, QueenslandAges 18–55 - NCT07257562Recruiting
Testing gut bacteria and amino acids to clear hepatitis B surface marker
This study tests whether a combination of a harmless gut bacterium (Bacteroides fragilis) and branched-chain amino acids (BCAAs, which are building blocks of protein) can help your body clear the hepatitis B surface antigen (HBsAg) from your blood. This may mean moving closer to a functional cure for chronic hepatitis B.
Fuzhou, FujianAges 18 years+ - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT07342881RecruitingPhase 1
Single dose study of pevifoscorvir in people with kidney impairment
This study tests how a single dose of the study drug, pevifoscorvir, is processed in people with different levels of kidney function. It helps understand if the dose needs to be adjusted for people with kidney problems.
Orlando, FloridaAges 18–75 - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT06777173Enrolling by invitation
Antiviral and Immunotherapy for Chronic Hepatitis B
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
BeijingAges 18–65 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT05403047RecruitingPhase 4
Preventing mom-to-baby hepatitis B with tenofovir
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
TokonbéréAges 16 years+ - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT07342868RecruitingPhase 1
Single dose study for liver health
This trial tests a single dose of an experimental drug called pevifoscorvir in people with moderate liver problems and in healthy people. It aims to see how the body processes the drug and if it is safe.
Orlando, FloridaAges 18–75 - NCT04690972Recruiting
Collection of blood and tissue samples for liver disease research
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
StrasbourgAges 18 years+ - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT05988879Recruiting
Functional cure for hepatitis B in HIV/HBV co-infection
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Guangzhou, GuangdongAges 18–65 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Huntington Park, CaliforniaAges 18 years+ - NCT06659588Recruiting
Study of chronic hepatitis risk in people with immune weaknesses
This study looks at people with certain immune system weaknesses to see if they are at risk for chronic hepatitis caused by a virus in the gut. Researchers want to understand how the immune system affects this infection.
ParisAges Any age - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Miami Beach, FloridaAges 18 years+
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b?
- Yes. Clin2 currently lists 171 recruiting chronic hepatitis b studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.